Small Business Resources, Business Advice and Forms from AllBusiness.com

Business Exchange

Beckman Coulter Ships New Image Processing-Based Cellular Analysis System; New Vi-CELL System Meets Demands of Rapidly Expanding...

Business Editors & Health/Medical Writers

Beckman Coulter, Inc. (NYSE:BEC) announced today the first orders for the company's new Vi-CELL(TM) cell viability analyzer have been shipped. The Vi-CELL automates the widely accepted trypan blue dye exclusion method for monitoring cell viability and can also be used for production control during the manufacturing stage of the biotech industry's rapidly expanding recombinant DNA process for the production of bio-active molecules.

Designed around a novel flow cell that ensures all cellular material being analyzed is always in focus, the Vi-CELL captures numerous images of the cellular population with its high resolution CCD (Charge Coupled Device) camera. The images are analyzed using a propriety algorithm for continuous tone (Grey-scale). Non-viable (dead) cells absorb the trypan blue stain as a consequence of their cellular membranes losing integrity. As a result, they become darker in color in relation to the viable cells present. It is this difference in color (tone) that is measured using the Vi-CELL.

"The Vi-CELL is the first of a series of instruments that will utilize image based technologies to address specific identified application opportunities for cellular research," said Ian Ley, particle characterization strategic marketing manager for Beckman Coulter. "As the world's leading provider of cellular solutions, these novel technologies allow us to further enhance our presence in the life sciences market and address specific elements of the newly emerging cellular based drug discovery, particularly in the proteomics sector."

Beckman Coulter's Vi-CELL offers numerous advantages over the current manual method. For instance, a typical analysis using the Vi-CELL system will measure thousands of cells, ensuring a high degree of accuracy and reproducibility. The manual hemocytometer method, by comparison, typically measures less than one hundred cells and is very subjective. The Vi-CELL software featuring electronic signature capability, will aid with 21 CFR Part 11 compliance and is available with a full equipment qualification system (IQ,OQ,PQ) to address validation issues.

In addition to viability, the Vi-CELL reports parameters including size, circularity (shape), cell count, viable cells within a population, and total and viable cells per milliliter. A major feature in the software is the bio-processing tracking option, which allows for complete tracking of a bio-process (fermentation) over time, reporting such parameters as doubling time and growth rates. For maximum throughput, the system can be configured with a 12-position continuous feeding auto-sampler. Vi-Cell adheres to Standard Operating Methods, ensuring the benefit of standardization, while offering the maximum flexibility for users monitoring multiple cell lines.

Beckman Coulter, Inc. is a global biomedical company, headquartered in Fullerton, California. The company develops and markets instruments, chemistries, software and supplies that simplify and automate laboratory processes throughout the biomedical testing continuum. Through pioneering medical research and drug discovery, specialty testing, and patient care diagnostics, Beckman Coulter supports all phases of the battle against disease. Annual sales for the company totaled $2 billion in 2001, with 62% of this amount generated by recurring revenue from supplies, test kits and services. For more information, visit www.beckmancoulter.com.

In addition, make sure to read these articles:

  • Beckman Coulter Ships New Genetic Analysis System;...
  • Business Editors/Health/Medical Writers FULLERTON, Calif.--(BUSINESS WIRE)--Sept. 9, 2003 Beckman Coulter, Inc. (NYSE:BEC) has begun shipping its new CEQ(TM) 8800 Genetic Analysis System, which offers sample ......
  • Visualize Licenses Bioinformatics Software to...
  • PHOENIX -- Visualize Inc. today announced it has signed a royalty bearing software development and licensing agreement with Beckman Coulter Inc. Under the terms of ......
  • Beckman Coulter Reports Second Quarter 1998Results.
  • FULLERTON, Calif.--(BW HealthWire)--July 20, 1998--Beckman Coulter, Inc. (NYSE:BEC) announced today that second quarter 1998 sales were $435 million and first half 1998 sales were $834 ......
  • New Beckman Coulter System Provides Broad,...
  • Business Editors & Health/Medical Writers BIOWIRE2K FULLERTON, Calif.--(BW HealthWire)--Jan. 28, 2002 Beckman Coulter, Inc. (NYSE:BEC) introduces the CEQ(TM) 8000 Genetic Analysis System, which automates and ......
  • Beckman Coulter's New CEQ 2000XL DNA...
  • Business Editors & Health/Medical Writers BIOWIRE2K FULLERTON, Calif.--(BW HealthWire)--July 18, 2000 Beckman Coulter, Inc. (NYSE:BEC) today introduced the CEQ(TM) 2000XL DNA Analysis System, the next ......
  • Beckman Coulter Announces First Quarter...
  • Business Editors/Health and Medical Writers FULLERTON, Calif.--(BW HealthWire)--May 1, 2000 Beckman Coulter, Inc. (NYSE: BEC) announced today first quarter results for the period ending March ......
  • Beckman Coulter Announces Net Earnings Growth of...
  • Business Editors FULLERTON, Calif.--(BUSINESS WIRE)--July 31, 2000 Beckman Coulter, Inc. (NYSE:BEC) announced today second quarter and first half results for the periods ended June 30, ......
  • Beckman Coulter and SRL, Inc. Enter...
  • Business Editors/Health & Medical Writers FULLERTON, Calif.--(BW HealthWire)--May 28, 2002 Beckman Coulter, Inc. (NYSE:BEC) announced today that they have signed an agreement with SRL, Inc....
  • Beckman Coulter and Medical and...
  • Business Editors & Health/Medical Writers FULLERTON, Calif.--(BW HealthWire)--May 30, 2002 Beckman Coulter, Inc. (NYSE:BEC) announced today they have entered a strategic partnership with Medical and ......
  • Beckman Coulter Announces New Systems...
  • Business Editors & Health/Medical Writers BIOWIRE2K FULLERTON, Calif.--(BUSINESS WIRE)--Jan. 27, 2003 Beckman Coulter, Inc. (NYSE:BEC) today introduced two new systems for protein discovery: ProteomeLab PF ......
  • Beckman Coulter Settles Patent Infringment...
  • Business Editors & Health/Medical Writers FULLERTON, Calif.--(BUSINESS WIRE)--Dec. 5, 2002 Beckman Coulter, Inc. (NYSE:BEC) announced today that its Board of Directors ratified a settlement with ......
  • Fitch Downgrades Beckman Coulter's Ratings to...
  • CHICAGO -- Fitch Ratings has downgraded Beckman Coulter's issuer default, senior unsecured debt and bank loan debt ratings to 'BBB' from 'BBB+', in light of ......
  • Fitch Affirms Beckman Coulter Net Lease P-T Ctfs,...
  • CHICAGO -- Fitch affirms the following class of the Beckman Coulter, Inc., series BC 2000-A, pass-through certificates: --$109.7 million class A at 'BB-'. The loans ......
  • Beckman Coulter and Bio-Rad Agree to New...
  • Business Editors/Health and Medical Writers BIOWIRE2K FULLERTON, Calif.--(BW HealthWire)--Sept. 11, 2000 Beckman Coulter, Inc (NYSE:BEC) announced today that it has agreed with Bio-Rad Laboratories, Inc....
  • Beckman Coulter.
  • Beckman Coulter introduced the nanoVette microliter accessory for its DU 800 and DU 730 UV/Vis spectrophotometers for sample sizes as small as 0.7 [micro]....